Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised Curosurf in preterm neonates with RDS
NCT03235986Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2017
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Poractant alfa in respiratory distress syndrome (RDS), sponsored by Chiesi Farmaceutici S.p.A.. Started Aug 2017; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT03235986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235986.